I Bio, Inc. IBIO
We take great care to ensure that the data presented and summarized in this overview for iBio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in IBIO
Top Purchases
Top Sells
About IBIO
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Insider Transactions at IBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
4,881
-2.6%
|
$0
$0.27 P/Share
|
|
Oct 03
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
5,267
-2.73%
|
$0
$0.3 P/Share
|
|
Oct 02
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
4,215
-2.14%
|
$0
$0.31 P/Share
|
|
Aug 28
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
5,011
-2.48%
|
$0
$0.31 P/Share
|
|
Jul 27
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
4,515
-1.09%
|
$0
$0.51 P/Share
|
|
Jul 12
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
47,020
-18.55%
|
$0
$0.59 P/Share
|
|
Jun 26
2023
|
Martin Brenner Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,833
+23.03%
|
-
|
|
Jun 22
2023
|
Martin Brenner Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
75,833
-29.92%
|
-
|
|
Jun 21
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
4,184
-0.54%
|
$0
$0.68 P/Share
|
|
May 22
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
4,182
-0.8%
|
$0
$0.94 P/Share
|
|
Apr 24
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
4,382
-1.65%
|
$4,382
$1.2 P/Share
|
|
Mar 31
2023
|
Felipe Duran Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+48.62%
|
-
|
|
Mar 31
2023
|
Martin Brenner Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+15.81%
|
-
|
|
Mar 23
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
5,213
-2.35%
|
$10,426
$2.13 P/Share
|
|
Feb 21
2023
|
Martin Brenner Officer |
SELL
Open market or private sale
|
Direct |
3,976
-1.76%
|
$3,976
$1.77 P/Share
|
|
Jan 20
2023
|
Martin Brenner Officer |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+36.58%
|
-
|
|
Nov 11
2022
|
Robert Matthew Lutz Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,057
+49.48%
|
-
|
|
Nov 11
2022
|
Martin Brenner Officer |
BUY
Grant, award, or other acquisition
|
Direct |
95,348
+50.0%
|
-
|
|
Mar 10
2022
|
Robert Matthew Lutz Officer |
SELL
Open market or private sale
|
Direct |
24,625
-10.61%
|
$0
$0.35 P/Share
|
|
Dec 07
2021
|
Randy Joe Maddux Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
37,243
-12.05%
|
$0
$0.68 P/Share
|